BioPharmSignal logoBioPharmSignal

Biotech News

Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026

Salarius Pharmaceuticals (SLRX)Salarius PharmaceuticalsConference / presentation

Live video webcast with Rick Pierce, Chief Executive Officer of Decoy Therapeutics, on Thursday, April 9 th at 4:00 PM ET Register for the event here CAMBRIDGE, Mass. and HOUSTON, April 6, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a biotechnology company

Related news

FATEFate Therapeutics2026-09-03 11:00 EST

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

KURAKura Oncology2026-09-01 11:15 EST

Kura Oncology to Participate in Three Investor Conferences in September

CHRSCoherus BioSciences, Inc.2026-08-31 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

MGNXMacroGenics2026-09-09 20:05 EST

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

ELVNEnliven Therapeutics2026-08-31 22:05 EST

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

LYELLyell Immunopharma2026-09-14 11:00 EST

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference

FATEFate Therapeutics2026-09-09 11:00 EST

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

EXELExelixis2026-09-01 20:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

LEGNLegend Biotech Corporation2026-09-01 12:00 EST

Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference

REGNRegeneron Pharmaceuticals2026-08-19 20:05 EST

Regeneron Announces Investor Conference Presentations

View all latest news

Salarius Pharmaceuticals

Salarius Pharmaceuticals is a biotechnology company focused on oncology and epigenetic or related cancer biology. Its story is built around seeking targeted cancer therapies for difficult tumors.

Recent company news

SLRXSalarius Pharmaceuticals2026-04-27 12:45 EST

Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston

SLRXSalarius Pharmaceuticals2026-04-09 12:36 EST

Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline

SLRXSalarius Pharmaceuticals2026-04-06 13:15 EST

Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026

SLRXSalarius Pharmaceuticals2026-04-02 13:00 EST

Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

SLRXSalarius Pharmaceuticals2026-03-11 12:30 EST

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States